Pediatric Autism

Description

A clinical study to evaluate Lumateperone as a potential option to help manage irritability in teens with autism, ages 13-17. This study offers families the opportunity to explore a new, research-backed approach to managing irritability symptoms associated with autism. Participants will receive study-related care from dedicated healthcare providers and contribute to advancing autism research.

CONTACT US ABOUT AUTISM TRIAL
Eligibility Criteria

We’re currently enrolling teens 13-17 with: a confirmed autism diagnosis, symptoms of irritability associated with ASD, and mild to moderate intellectual disability

Intervention

This 6-week study includes regular visits with healthcare providers, where study medication or placebo will be administered and monitored. If participants successfully complete the 6-week treatment period, they may be eligible for a follow-up safety study.